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Over 150 unique ABCA1 mutations have been reported 
and impaired ABCA1 activity associated with mutations in 
ABCA1 is a major genetic cause of low HDL-C levels ( 1, 2 ). 
The reduced function of many of these has been attributed 
to intracellular retention and prolonged residence in the 
endoplasmic reticulum (ER), leading to mislocalization to 
the plasma membrane ( 1, 3, 4 ). Mutations that cause mis-
folding are an established cause of mislocalization for 
other membrane transporter proteins ( 5 ). Treatment with 
chemical chaperones can improve the folding, traffi cking, 
and function of such proteins ( 5 ). Here, we investigate the 
effect of the chemical chaperone, sodium 4-phenylbutyrate 
(4-PBA) on the localization and function of ABCA1. 
 4-PBA is a short-chain fatty acid that can rescue the det-
rimental phenotype of misfolded, mislocalized proteins in 
vitro and in vivo ( 6 ). In particular, 4-PBA can restore func-
tionality to mutant ATP-binding cassette transporters in-
cluding ABCA3, ABCD2, ABCC6, ATPB7, and CFTR ( 7–11 ), 
which prompted its use here. 4-PBA has been used in a 
wide range of clinical applications including routine treat-
ment of patients with cystic fi brosis, thalassemias, urea cy-
cle disorders, and cancer ( 6 ). Treatment of CFTR mutants 
responsible for cystic fi brosis has shown that 4-PBA amelio-
rates ER retention and is suffi cient to restore protein func-
tion in vitro and in vivo ( 11, 12 ). Mechanisms for its action 
include the ability to act as a chaperone ( 13 ), reduce ER 
stress ( 14 ), transcriptionally upregulate chaperone proteins 
( 15 ), provide histone deactylase inhibitor activity ( 16 ), and 
scavenge ammonia ( 17 ). 
 The application of chemical chaperones to ABCA1 has 
not been described; however, mutant ABCA1 proteins 
with aberrant cellular localization are suitable candidates 
for such treatment. We investigated the impact of 4-PBA 
on nine naturally occurring ABCA1 missense mutants. Six 
 Abstract  Mutations in the ATP-binding cassette transporter 
A1 (ABCA1) are a major cause of decreased HDL choles-
terol (HDL-C), which infers an increased risk of cardiovas-
cular disease (CVD). Many ABCA1 mutants show impaired 
localization to the plasma membrane. The aim of this study 
was to investigate whether the chemical chaperone, sodium 
4-phenylbutyrate (4-PBA) could improve cellular localiza-
tion and function of ABCA1 mutants. Nine different ABCA1 
mutants (p.A594T, p.I659V, p.R1068H, p.T1512M, p.Y1767D, 
p.N1800H, p.R2004K, p.A2028V, p.Q2239N) expressed in 
HEK293 cells, displaying different degrees of mislocal-
ization to the plasma membrane and discrete impacts on 
cholesterol effl ux, were subject to treatment with 4-PBA. 
Treatment restored localization to the plasma membrane 
and increased cholesterol effl ux function for the majority 
of mutants. Treatment with 4-PBA also increased ABCA1 
protein expression in all transfected cell lines. In fi broblast 
cells obtained from low HDL-C subjects expressing two of 
the ABCA1 mutants (p.R1068H and p.N1800H), 4-PBA in-
creased cholesterol effl ux without any increase in ABCA1 
expression.  Our study is the fi rst to investigate the effect 
of the chemical chaperone, 4-PBA on ABCA1 and shows 
that it is capable of restoring plasma membrane localiza-
tion and enhancing the cholesterol effl ux function of mu-
tant ABCA1s both in vitro and ex vivo. These results suggest 
4-PBA may warrant further investigation as a potential ther-
apy for increasing cholesterol effl ux and HDL-C levels. —
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supplemented with 10% FBS (Bio International; Auckland, New 
Zealand), 2 mM L-glutamine, 0.25 µg/ml amphotericin B, 100 
U/ ml penicillin, and 100 µg/ml streptomycin at 37°C in a hu-
midifi ed environment with 5% CO 2 . Unless otherwise stated, all 
cell culture reagents were purchased from Invitrogen (Carlsbad, 
CA). A 100 mM stock of 4-PBA (Tocris Bioscience; Ellisville, MO) 
was made using sterile water and diluted to a 10 mM working 
stock in serum-free culture medium. Culture medium was re-
placed with 4-PBA supplemented serum-free medium for 24 h 
prior to the experiment endpoint. ApoA-I protein used for func-
tional experiments was isolated from normolipidemic human 
plasma according to the method of Brace et al. ( 21 ), and was 
presented to cells in serum-free medium, supplemented with 10 mM 
4-PBA when appropriate. 
 Cellular transfection protocol 
 Twenty four hours after seeding in 12-well culture plates, 
HEK293 cells were transiently transfected with the ABCA1-GFP 
cDNA expression vectors or the ABCA1 promoter vector using 
FuGENE 6 (Roche) transfection reagent at a ratio of 3:1 reagent 
(µL) to DNA (µg). Serum-free DMEM was mixed with FuGENE 6 
and incubated at room temperature for fi ve minutes. The plas-
mid DNA was added, mixed well, and incubated for a further 20 min 
at room temperature. Culture medium was replaced with fresh 
medium (containing [ 3 H]cholesterol when required) and trans-
fection mix was added to the cells in a drop-wise manner. 
 Cholesterol effl ux assays 
 Cholesterol effl ux assays were performed using primary fi bro-
blast cells and transfected HEK293 cells as described previously 
( 20 ). Twenty four hours after cells were seeded, the culture me-
dium was replaced with fresh medium containing 0.5 µCi/well 
[ 3 H]cholesterol (Amersham Biosciences; Piscataway, NJ). HEK293 
cells were transiently transfected with 1 µg ABCA1-GFP cDNA ex-
pression vector per well immediately following the addition of 
the [ 3 H]cholesterol. Following a 48 h incubation, to allow for cel-
lular incorportation of the labeled cholesterol and expression of 
the transfected cDNA in HEK293 cells, the cells were equilibrated 
in serum-free medium for 12 h and were then incubated in se-
rum-free medium containing 10 µg/ml apoA-I protein. After 8 
(fi broblast) or 12 (HEK293 cells) h incubation the medium was 
collected and centrifuged at 3,000  g for 5 min to pellet cellular 
debris and the cellular lysates were harvested from the culture 
plate by addition of 0.1 M NaOH. The tritium decay over 5 min 
was determined for both the media and cellular fractions using 
Optiphase Hisafe II scintillation fl uid (Perkin Elmer; Boston, MA). 
Cholesterol effl ux was calculated as the proportion of total radio-
activity present in the medium fraction. Nonspecifi c effl ux in the 
absence of apoA-I was determined and subtracted from each ex-
perimental measurement. 
 Confocal microscopy 
 The cellular localization of ABCA1-GFP proteins was exam-
ined using confocal microscopy ( 19 ). Transfected HEK293 cells 
were cultured on poly- L -ornithine coated glass coverslips and 48 h 
following transfection the cells were incubated in serum-free 
medium overnight. The following day, cells were incubated with 
fresh medium containing 10 µg/ml apoA-I for 6 h. Cells were 
fi xed using 4% formaldehyde and stained with 5 µg/ml Alex-
aFluor594 Wheat Germ agglutinin (Invitrogen) to label cell 
membranes and mounted on glass slides. Images were ob-
tained using a Zeiss LSM 510 confocal microscope with the 
Argon (488 nm) and HeNe (633 nm) lasers and were analyzed 
using the Zeiss LSM Image Examiner software. The Pearson’s 
correlation coeffi cient between the GFP and AlexaFluor594 
of the ABCA1 mutations were previously identifi ed in low 
HDL-C subjects and included three uncharacterized muta-
tions, p.I659V, p.R2004K, and p.A2028V ( 18 ) and three 
variants, p.R1068H, p.T1512M, and p.N1800H, known to 
have reduced localization and cholesterol effl ux ( 19, 20 ). 
We identifi ed a further three novel mutations, p.A594T, 
p.Y1767D, and p.Q2239N, and these were also included in 
this study. We hypothesized that effl ux function would be 
improved for mutants that are dysfunctional as a result of 
protein mislocation. The results presented here provide the 
fi rst evidence that chaperone-mediated restoration of mu-
tant ABCA1 cellular localization improves effl ux function. 
 MATERIALS AND METHODS 
 ABCA1 gene analysis 
 The study was approved by the Lower South Regional Ethics 
Committee. All subjects gave informed consent and all proce-
dures were in accordance with institutional guidelines. Screening 
of the ABCA1 gene in 10 low HDL-C subjects (<0.8 mmol/L) was 
performed by PCR amplifi cation and sequencing of all 50 exons 
of the ABCA1 gene ( 20 ). Primer sequences are provided in sup-
plementary Table I. All PCR reactions contained 10 ng DNA, 
14 pmol each of the forward and reverse primers, 1× Roche Fast-
start Taq PCR buffer (2 mM MgCl2), 200   M each dNTP, 1 U 
Faststart Taq DNA polymerase (Roche; Mannheim, Germany) 
and MilliQ water to a fi nal reaction volume of 20   l. A two-step 
PCR amplifi cation program was used and consisted of an initial 
denaturation step of 5 min at 95°C followed by 10 amplifi cation 
cycles of denaturation at 95°C for 48 s, annealing at 63°C for 48 s, 
followed by extension at 72°C for 48 s. These cycles were repeated 
a further 25 times with the annealing temperature dropped to 
61°C. A fi nal extension of 10 min at 72°C was performed and the 
reactions were held at 4°C. A decreased annealing temperature 
combination of 59 to 57°C was used to amplify exons 17 and 44. 
Annealing at 61 to 59°C was used for exons 38 and 39 and 66 to 
64°C for exons 10, 15, 23, and 24 to eliminate the amplifi cation 
of nonspecifi c products. Protein residue numbering was accord-
ing to NP_005493.2. 
 Mutant ABCA1-green fl uorescent protein (GFP ) expression 
vectors under control of the heterologous cytomegalovirus (CMV) 
promoter were created by PCR site-directed mutagenesis (primers 
are provided in supplementary Table II) of a wild-type pCIneo-
ABCA1-GFP cDNA vector (kindly provided by Professor Chris-
tiane Albrecht, Institute of Biochemistry and Molecular Medicine, 
University of Bern). One mutation was induced per round of 
mutagenesis using high fi delity, nonstrand displacing, Pfu DNA 
polymerase (Promega; Madison, WI). PCR reactions contained 
1× Pfu Buffer, 200 µM dNTPs, 0.5 µmol each of the forward and 
reverse mutagenic primers, 75 ng template plasmid DNA, 0.4 U 
Pfu polymerase, and MilliQ water to make up a 20 µL reaction 
volume. Cycling parameters consisted of initial denaturation at 
98°C for 2 min followed by 35 cycles of denaturation at 98°C for 
40 s, annealing at 55°C for 1 min, and extension at 72°C for 15 s 
per kb of template DNA. A fi nal extension at 72°C for 10 min was 
performed. The mutation position and the entire cDNA insert 
for all vectors were verifi ed by sequencing. 
 Cell culture 
 Primary fi broblast cultures were established from 2 mm punch 
biopsies ( 20 ) and were cultured in Advanced DMEM. HEK293 
cells were obtained from the American Type Tissue Collection 
(Manassas, VA) and maintained in DMEM. Both media were 
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 RESULTS 
 ABCA1 mutants with impaired localization have reduced 
cholesterol effl ux function 
 We identified three novel ABCA1 variants, p.A594T, 
p.Y1767D, and p.Q2239N, in heterozygote form in three in-
dividuals with HDL-C levels of 0.61, 0.17, and 0.37 mmol/L, 
respectively. The individual heterozygote for p.Y1767D was 
also heterozygote for the p.N1800H ABCA1 mutation. The 
position of all ABCA1 protein variants investigated within 
this study is shown in  Fig. 1 . 
 We first characterized the three novel ABCA1 mu-
tants and three previously identifi ed but uncharacterized 
mutants (p.I659V, p.R2004K, and p.A2028V) in HEK293 
cells, which lack the endogenous ABCA1 protein (see 
supplementary  Fig. I ). Investigation of the six uncharac-
terized mutations in transfected HEK293 cells showed 
the p.A594T, p.I659V, p.Y1767D, p.R2004K, and p.A2028V 
mutants to have various degrees of mislocalization ( Fig. 2A ). 
Mislocation was indicated by areas of ABCA1-GFP (green) 
signal inside the cell as opposed to a yellow signal around 
the plasma membrane indicating normal localization 
of ABCA1-GFP to the plasma membrane (red). Areas of 
mislocalized ABCA1-GFP are indicated by arrows in  Fig. 2A 
with the p.Y1767D and R2004K mutants being the most 
affected. The mislocalization of mutant ABCA1s was 
associated with a reduced cholesterol efflux function 
compared with wild-type-GFP ABCA1 ( Fig. 2B ) with the 
p.Y1767D mutant being the most affected (30.3% the 
effl ux of wild-type). The p.Q2239N mutation did not af-
fect plasma localization or cholesterol effl ux function. 
A similar amount of radioactive cholesterol was incor-
porated into mutant and wild-type cells and the non-
specfi c effl ux did not differ signfi cantly between ABCA1 
genotypes. 
 The ABCA1-GFP protein level in transfected HEK293 
cells was assessed by Western blotting using an anti-GFP 
antibody ( Fig. 2C ). Quantifi cation of the Western blot 
images showed the ABCA1-GFP signal to be comparable 
across all genotypes (as assessed using one-way ANOVA, 
 Fig. 2D ), which indicates all ABCA1-GFP proteins were 
expressed to a similar level. 
 4-PBA rescues mutant ABCA1 localization and improves 
cholesterol effl ux function in transfected HEK293 cells 
 4-PBA treatment was applied to the six uncharacter-
ized ABCA1 mutants as well as to three mutants that we 
have previously shown to have reduced cholesterol effl ux 
function, p.R1068H ( 19 ), p.T1512M ( 20 ), and p.N1800H 
( 20, Fig. 1 ). Treatment of transfected HEK293 cells with 
4-PBA improved plasma membrane localization for all of 
the mislocated mutants ( Fig. 3A ).  This was shown by a 
visible reduction in the intracellular GFP green signal 
(indicated by arrows in the most affected mutants) and 
a corresponding increase in yellow signal around the 
plasma membrane, indicating colocalization of ABCA1-
GFP to the plasma membrane (red signal). Quantifi ca-
tion of the colocalization of the ABCA1-GFP signal with 
plasma membrane signal showed a signifi cantly reduced 
signal was calculated from images using the Colocalisation Finder 
plugin of the ImageJ software. 
 Protein isolation and Western blot analysis 
 Western blots of cell lysates were performed as described pre-
viously ( 19 ). Cells were grown to confl uence and lysed in RIPA 
buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS] supplemented with complete 
mini protease inhibitors (Roche). Lysates were separated by 
SDS-PAGE using 7.5% gels and transferred to nitrocellulose 
membrane. Membranes were probed with a polyclonal anti-
body to actin (A5060: Sigma; St. Louis, MO) and either a mono-
clonal antibody to ABCA1 (ab18180: AbCam; Cambridge, UK) 
or a polyclonal antibody to GFP (ab290, AbCam). Quantifi cation 
of band intensity was performed using ImageQuant TL software 
(Amersham Biosciences). 
 RNA isolation and quantitative RT-PCR 
 Total RNA was isolated from cells cultured to confl uence 
using the RNeasy mini kit (Qiagen, Hilden, Germany). Isolated 
RNA was treated with DNase I (Qiagen) and 1 µg was reverse 
transcribed to cDNA using Transcriptor Reverse Transcriptase 
(Roche) according to the manufacturer’s instructions. Quantita-
tive RT-PCR was performed using a LightCycler® 480 (Roche) 
with the SYBR Green Master Mix kit (Roche). Primer sequences 
are provided in supplementary Table III. Reactions were set up in 
96-well plates and contained 1 µM forward and reverse primer, 
5 µL SYBR Green I Master (Roche), 2 µL diluted cDNA and ster-
ile water to a fi nal volume of 10 µL. Amplifi cation of the template 
was performed using an initial denaturation step of 95°C for 
5 min followed by 40 to 50 cycles of denaturation at 95°C, anneal-
ing at 61°C for 5 s, and extension at 72°C for 8 s. There was a 
single data acquisition point at the end of each extension. The 
fi nal step of each run was a melt curve analysis with continuous 
data acquisition and consisted of denaturing at 95°C for 30 s, 
cooling to 65°C, and heating with a ramp rate of 0.11°C per sec-
ond to 95°C. ABCA1 mRNA expression relative to GAPDH was 
calculated from in-run standard curves. 
 Luciferase reporter gene assays 
 The transcriptional response of the native ABCA1 promoter 
to 4-PBA was examined using HEK293 cells transfected with 
luciferase reporter constructs. To create an ABCA1 promoter 
reporter vector, a 715 bp region (position -714 to +1) of the wild-
type ABCA1 promoter was amplifi ed and cloned into the pCR2.1 
entry vector (Invitrogen). A 700 bp region of the promoter (posi-
tion   699 to +1) was then subcloned from the pCR2.1 vector into 
the pGL4.10 reporter vector containing fi refl y luciferase (Promega; 
Madison, WI) using primers containing EcoRV and  Hin dIII re-
striction sites (primers are provided in supplementary Table IV). 
Cells were transiently cotransfected with 0.5 µg of the ABCA1-
promoter pGL4.10 vector, and 5 ng of the phRL-SV40 vector, 
designed to constitutively expression renilla luciferase. Growth 
medium was replaced 24 h following transfection with fresh 
medium, containing 4-PBA when required. After a further 24 h, 
cell lysates were harvested and assayed for renilla and fi refl y lu-
ciferase activity using the Dual Luciferase® Reporter Assay Sys-
tem (Promega). Firefl y luciferase measurements were normalized 
to renilla measurements and expressed relative to untreated 
ABCA1 promoter activity as 1.0. 
 Data analysis 
 Data are expressed as mean + SEM unless otherwise stated. 
Differences of means were assessed using the Student’s  t -test or 
one-way ANOVA with Bonferroni posthoc comparisons. 
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 Upon 4-PBA treatment, effl ux function was signifi cantly 
increased relative to the untreated level for the p.R1068H, 
p.T1512M, p.Y1767D, p.N1800H, p.R2004K, and p.A2028V 
mutants ( Fig. 3B ). There was no change in cholesterol 
effl ux function for the mock transfected cells, confi rm-
ing that the 4-PBA treatment was specifi cally acting on 
the ABCA1-GFP proteins. Two of the three most severely 
colocalization in most of the mutant cell lines compared 
with wild-type in the untreated state (supplementary  Fig. II ). 
Treatment with 4-PBA induced a signifi cant increase in co-
localization for the p.A594T, p.R1068H, p.T1512M, p.Y1767D, 
p.N1800H, and p.R2004K mutants. Treatment with 4-PBA 
did not affect the colocalization of the wild-type ABCA1-
GFP protein (supplementary  Fig. II ). 
 Fig.  1. Schematic of the ABCA1 protein showing the position of the nine mutants studied. 
 Fig.  2. Mislocalization of ABCA1 to the plasma membrane correlates with reduced cholesterol effl ux func-
tion in transfected HEK293 cells. A: Confocal microscopy of HEK293 cells expressing ABCA1-GFP (green), 
counterstained with AlexaFluor594 WGA membrane stain (red); regions of yellow indicate colocalization of 
ABCA1-GFP with membrane. Scale bars represent 10 µm and arrows indicate areas of substantial intracellu-
lar GFP signal. B: Cholesterol effl ux from transfected cells to 10 µg/ml apoA-I protein. C: Western blot and 
(D) quantifi cation for ABCA1-GFP protein level. Data represent mean + SEM of at least three experiments 
performed in quadruplicate for effl ux and duplicate for protein quantifi cation. *** p  < 0.001 compared with 
wild-type or to all other values when assessed by ANOVA (D). 
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 4-PBA improves mutant ABCA1 effl ux function 
independent of protein level in primary fi broblasts 
 We assessed the effect of 4-PBA treatment in the con-
text of the native ABCA1 promoter using available p.R1068H, 
p.N1800H, and wild-type primary fi broblast cell lines 
( 19, 20 ). Fibroblasts were obtained from two p.R1068H 
heterozygote carriers (RH1 and RH2), two p.N1800H 
heterozygote carriers (NH1 and NH2), and two ABCA1 
wild-type subjects (WT1 and WT2). The mutant carriers 
RH1, RH2, and NH1 were confi rmed to carry no other 
ABCA1 mutations on either their mutant or wild-type 
alleles. We had previously determined that subject NH2 
was also heterozygous for the p.C978fsX988 mutation, 
which encodes a truncated protein that is functionally 
null and in this individual was present on a seperate allele 
to the p.N1800H mutation ( 20 ). 
mislocated mutants, p.Y1767D, and p.N1800H, showed a 
restored effl ux function that was equivalent to wild-type 
untreated cells. However, the cholesterol effl ux of the 
p.R1068H mutant was unable to be restored to wild-type 
levels. Interestingly, the cholesterol effl ux of the wild-type 
ABCA1-GFP transfected cells was also signifi cantly increased 
after 4-PBA treatment ( Fig. 3B ). Treatment of transfected 
HEK293 cells with 4-PBA increased ABCA1-GFP protein 
level by a similar fold increase (1.4- fold to 1.8-fold) across 
all genotypes including wild-type ( Fig. 3C, D ). Further-
more, 4-PBA increased the level of wild-type and mutant 
ABCA1-GFP mRNA (1.8-fold to 2.1-fold) in transfected 
cells ( Fig. 4 ). These results indicate that 4-PBA promotes a 
similar transcriptional upregulation of the heterologous 
promoter within the wild-type and mutant ABCA1-GFP 
vectors that results in an increased ABCA1 protein level. 
 Fig.  3. The chemical chaperone 4-PBA restores membrane localization and rescues cholesterol effl ux function of ABCA1 mutants. Trans-
fected HEK293 cells were treated with 10 mM 4-PBA for 24 h. A: Confocal microscopy of cells expressing ABCA1-GFP (green) counter-
stained with AlexaFluor594 WGA membrane stain (red); regions of yellow indicate colocalization of ABCA1-GFP with membrane. Scale 
bars represent 10 µm and arrows indicate areas of substantial intracellular GFP signal. B: Cholesterol effl ux from ABCA1-GFP transfected 
cells to 10 µg/ml apoA-I. C: Western blot and (D) quantifi cation of foldchange in ABCA1-GFP protein level with 4-PBA treatment. Data 
represent mean + SEM of two experiments performed in quadruplicate for effl ux and duplicate for Western blot protein quantifi cation. 
* p  < 0.05, ** p  < 0.01, *** p  < 0.001 compared with untreated wild-type value (symbols directly above error bars) and for treated versus un-
treated values of the same genotype (symbols above lines). For (D), the comparison was to all other values, as assessed by ANOVA. 
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We hypothesized that restoring localization of mutant 
ABCA1 proteins would improve their function. We show 
that the chemical chaperone 4-PBA can restore localiza-
tion of mutant ABCA1 proteins and enhance their choles-
terol effl ux function. Our study is the fi rst application of a 
chemical chaperone treatment to ABCA1 and our results 
highlight that correct localization of ABCA1 is a major fac-
tor determining its function. 
 Our analysis in transfected HEK293 cells using nine 
different ABCA1 missense mutants with varying degrees 
of mislocalization showed that mislocalization coincided 
with a loss in cholesterol effl ux function in some of the 
mutants. Treatment of the mutant cell lines with 4-PBA 
ameliorated intracellular retention and improved plasma 
membrane localization for all mislocated mutants. Most 
importantly, the correction of localization restored effl ux 
 The cholesterol effl ux function of the mutant fi broblast 
cell lines was lower than the effl ux from wild-type cells 
( Fig. 5A ) as previously shown ( 19, 20 ). After treatment 
with 4-PBA, the cholesterol effl ux function of wild-type 
ABCA1 fi broblast cells was reduced (signifi cantly in the 
case of WT2). In contrast, there was a clear trend for 
increased effl ux in the mutants fi broblast cells with sta-
tistically signifi cant increases for the p.R1068H heterozy-
gote RH1 ( p < 0.05) and the p.N1800H heterozygote 
NH2 ( p < 0.001). Despite this improvement in effl ux func-
tion in the mutant cell lines, the effl ux remained 34.6–
65.3% that of untreated wild-type cells ( p < 0.001,  Fig. 5A ). 
It was noted that the increase in cholesterol effl ux pro-
moted by 4-PBA in the p.N1800H fi broblasts was not as 
striking as that seen in HEK293 cells transfected with 
this mutant where 4-PBA promoted cholesterol effl ux 
back up to untreated wild-type levels. 
 In contrast to transfected HEK293 cells, the ABCA1 pro-
tein level was decreased for all wild-type and mutant fi bro-
blast cell lines following 4-PBA treatment ( Fig. 5B ). There 
was a similar decrease in protein level for most cells lines 
with a greater decrease for RH2 cells ( p < 0.05), as assessed 
using one-way ANOVA ( Fig. 5C ). Further investigation us-
ing luciferase reporter assays showed 4-PBA to decrease 
the transcriptional activity of the native ABCA1 promoter 
( Fig. 6 ), indicating the lower protein level in treated fi bro-
blasts to be the result of transcriptional downregulation of 
ABCA1 by 4-PBA. 
 DISCUSSION 
 The ABCA1 protein functions as a tetramer in the 
plasma membrane ( 22 ) where it facilitates the effl ux of 
cholesterol onto apoA-I to form HDL. The ABCA1 pro-
tein is very intolerant to structural change and many 
ABCA1 mutants exhibit misfolding and intracellular re-
tention ( 1, 3, 4 ), leading to a lack of functional protein at 
the plasma membrane and associated low HDL-C levels. 
 Fig.  4. 4-PBA increases ABCA1-GFP mRNA level in transfected 
HEK293 cells. HEK293 cells transfected with wild-type ABCA1-GFP 
were treated with 10 mM 4-PBA for 24 h, total mRNA was harvested, 
reverse transcribed, and ABCA1 mRNA level examined by quanti-
tative RT-PCR relative to GAPDH. Data represents mean + SEM for 
two experiments performed in duplicate. * p  < 0.05, ** p  < 0.01, 
*** p  < 0.001 compared with the untreated condition. 
 Fig.  5. Treatment with 4-PBA increases the function of mutant 
ABCA1 primary fi broblast cells and decreases protein expres-
sion. Fibroblast cultures established from wild-type (WT1, WT2), 
p.R1068H carriers (RH1, RH2) and p.N1800H carriers (NH1, 
NH2) were treated with 10 mM 4-PBA for 24 h. A: Cholesterol 
effl ux from fi broblast cells to 10 µg/ml apoA-I. B: Western blot 
and (C) quantifi cation of foldchange for ABCA1 protein level 
with 4-PBA treatment. Data represent the mean + SEM of two ex-
periments performed in quadruplicate for effl ux and in dupli-
cate for Western blot protein quantifi cation. * p  < 0.05, *** p  < 0.001 
compared with untreated values of both wild-type subjects (sym-
bols directly above error bars) and for treated versus untreated 
values for each subject (symbols above lines) or to all other val-
ues when assessed by ANOVA (C). 
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was restored by the two different treatments. Plasma mem-
brane localization of the p.Q597R protein was promoted 
with thapsigargin, an inducer of ER stress, whereas 4-PBA 
is known to alleviate ER stress ( 14 ) by acting as a chaper-
one itself ( 13 ) as well as inducing the expression of endog-
enous chaperone proteins ( 15 ). The exact nature of the 
mutation could also be important. Indeed, our data shows 
that the specifi c location of the mutation is an important 
determinant of the capacity for functional rescue. For 
example, the p.Y1767D mutant showed a much enhanced 
localization and dramatic increase in cholesterol effl ux 
after 4-PBA treatment whereas the effl ux function for the 
p.R1068H mutant remained low despite showing a similar 
enhancement in localization. The p.R1068H mutant, lo-
cated in the fi rst ATP binding domain, has been shown to 
be defective in oligomerisation ( 19 ) and it is likely that al-
though localization was improved for this mutant with 
4-PBA treatment, the oligomerisation and therefore effl ux 
function remained defective. 
 As well as restoring localization, 4-PBA treatment had 
the effect of increasing ABCA1 mRNA and protein ex-
pression in transfected HEK293 cells. This effect is most 
likely due to its histone deacetylase inhibitor action. 
The ABCA1 expression vectors used here are driven by 
a heterologous CMV promoter and histone deacetylase 
inhibitors are known to exert a transcriptional effect on 
the CMV promoter ( 24 ). Functional improvements for 
other mutant proteins by 4-PBA have been attributed to 
increased expression ( 8, 10, 25 ), which suggests a global 
effect on transcription. Interestingly, we observed an 
opposite transcriptional effect of 4-PBA in fi broblasts 
harboring mutant ABCA1 proteins. 4-PBA decreased the 
transcriptional activity of the native ABCA1 promoter, 
which was associated with a decrease in ABCA1 protein 
level in fi broblasts. ABCA1 is highly regulated by many 
factors at the transcriptional level and one possibile 
mechanism for the decrease in ABCA1 promoter activity 
promoted by 4-PBA is that it could reduce the expression or 
activity of transcriptional regulators. As a fatty acid, 4-PBA 
may regulate transcription in a manner similar to unsatu-
rated fatty acids that supress ABCA1 transcription through 
posttranslational antagonism of liver X receptor   ( 26 ). 
 The improvement in cholesterol effl ux of ABCA1 mutants 
in fi broblasts despite the reduction in ABCA1 protein ex-
pression indicates that ABCA1 function and expression 
can be uncoupled. This uncoupling is not seen in wild-
type fi broblasts where a decreased protein level is asso-
ciated with a decreased effl ux function. We are not the 
fi rst to observe an uncoupling effect of a drug on ABCA1 
function and expression. The cholesterol lowering drug 
probucol increases ABCA1 protein level by inhibiting its 
proteosomal degradation ( 27 ) but simultaneously in-
hibits effl ux function by inhibiting translocation to the 
plasma membrane ( 28 ). As such, probucol provides an 
inverse example to 4-PBA. 
 This study provides the fi rst evidence that the activity 
of mutant ABCA1s can be enhanced by the chemical 
chaperone 4-PBA through restoration of cellular localiza-
tion. 4-PBA is already approved for clinical use and our 
 Fig.  6. 4-PBA decreases transcriptional activity of the native 
ABCA1 promoter. Wild-type ABCA1 promoter activity in trans-
fected HEK293 cells, as measured by dual luciferase reporter assay. 
Data represents mean + SEM for two experiments performed in 
triplicate. *** p  < 0.001 compared with the untreated condition. 
function to the level of untreated wild-type transfected 
cells for the majority of mutants. The magnitude by which 
4-PBA rescued function was mutant-dependent as restored 
localization did not always result in a restoration of func-
tion, as was the case for the p.R1068H mutant. Interest-
ingly, despite no alteration to membrane localization, effl ux 
function of the wild-type protein was also increased by 
4-PBA. This is most likely due to the increase in total wild-
type ABCA1 protein level that was induced by 4-PBA in 
HEK293 cells. 
 For two of the most dramatically affected mutants, 
p.R1068H and p.N1800H, a functional improvement with 
4-PBA treatment was also confi rmed ex vivo using primary 
fi broblast cells. Although 4-PBA also increased the choles-
terol effl ux function of ABCA1 mutants in primary fi bro-
blast, the magnitude of the effect was much less than that 
seen in the HEK293 system. The lesser effect in fi broblasts 
may relate to the reduced expression of ABCA1 promoted 
by 4-PBA, which, for wild-type ABCA1, is associated with a 
reduced effl ux. This would be expected to dampen the 
magnitude of functional improvements in heterozygous 
mutant fi broblasts harboring a wild-type allele. This is sup-
ported by the results seen in the NH2 versus NH1 fi bro-
blasts. The NH2 fi broblasts, which harbor a p.N1800H 
allele and a null allele, show a signifi cant improvement 
in function, yet the NH1 fi broblasts, which harbor a 
p.N1800H allele and a wild-type allele, show no signifi cant 
functional improvement. Hence, for fi broblasts only har-
boring mutant ABCA1 alleles, the increase in function 
promoted by 4-PBA refl ects the increase in mutant allele 
function whereas in fi broblasts harboring a mutant and 
wild-type ABCA1 allele, the increase in function promoted 
by 4-PBA refl ects the increase in mutant allele function 
combined with the decrease in wild-type allele function. 
 Improved positioning of ABCA1 at the plasma mem-
brane has been shown previously for a p.Q597R mutant 
under conditions of induced ER stress; however, in that 
instance, no improvement in effl ux activity was seen ( 23 ). 
This is in contrast with our results where the majority of 
the mutants showed signifi cant improvements in func-
tion, including the p.A594T mutant, which is of a similar 
location to p.Q597R. This discrepancy could be due to 
the mechanism by which plasma membrane localization 
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data suggests that it could provide an unexplored avenue 
for the development of HDL-C raising therapies to reduce 
CVD risk. The direct application of 4-PBA as a therapeutic 
agent, however, requires caution and more investigation. 
The effect of 4-PBA on ABCA1 expression and function in 
other cell types, particularly hepatic and macrophage cells, 
should be investigated because both are important cell 
types in determining HDL-C levels. In addition, the exact 
mechanism for how 4-PBA restores cellular localization re-
quires further investigation.  
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